Efectos de filgotinib en los parámetros del semen y las hormonas sexuales en pacientes masculinos con enfermedades inflamatorias: Resultados de los estudios de fase 2, aleatorizados, doble ciego, controlados con placebo MANTA y MANTA-RAy

Reinisch, et al. show that filgotinib treatment has no effect on semen parameters for men with active inflammatory diseases. This contrasts with pre-clinical studies that showed fertility issues in male animals.

Men with active inflammatory diseases were treated with filgotinib for 13 weeks in MANTA and MANTA-RAy. These two trials were multinational, randomised, double-blind, placebo-controlled, parallel-group, phase 2 studies.